螺旋断层皮肤放疗(含全身皮肤放疗)治疗原发性皮肤淋巴瘤:骨髓抑制为相关不良事件
该研究回顾性分析了24例原发性皮肤淋巴瘤患者接受螺旋皮肤放疗(HSRT)的53个皮肤区域,多数为蕈样肉芽肿。HSRT对蕈样肉芽肿的总体缓解率达100%,但躯干和手臂照射常导致≥3级骨髓抑制(94.1%),并有1例5级白细胞减少死亡。结论认为HSRT可诱导暂时姑息效果,但全身皮肤电子束治疗(TSEBT)仍应作为覆盖全身皮肤的原发性皮肤淋巴瘤的标准治疗。
要点
- HSRT治疗蕈样肉芽肿的总体缓解率为100%,完全缓解率80.9%。
- 躯干和手臂HSRT导致≥3级骨髓抑制发生率高达94.1%。
- 发生1例HSRT相关5级白细胞减少死亡,需警惕血液学毒性。
核心结论
- HSRT靶向躯干和手臂皮肤可诱导暂时姑息效果,但会导致严重骨髓抑制。
- TSEBT仍应被视为覆盖全身皮肤的原发性皮肤淋巴瘤的标准治疗。
研究设计与样本
- 回顾性研究纳入2015年6月至2019年7月在本院接受HSRT的原发性皮肤淋巴瘤患者,包括7例注册临床试验(UMIN000022142)患者。
- HSRT分头颈、躯干和手臂、腿部三个皮肤区域进行。
- 共分析24例患者53个皮肤区域,中位随访13个月(范围2-50个月)。
主要发现
- 20例(83.3%)为蕈样肉芽肿(MF)。
- 53个皮肤区域中41个(77.4%)采用20 Gy分10次剂量方案。
- MF患者各HSRT治疗野的总体缓解率为100%,其中完全缓解38个(80.9%)、良好部分缓解4个(8.5%)、部分缓解5个(10.6%)。
- 8例接受序贯全身皮肤照射的MF患者完全缓解率达100%。
- MF患者首次HSRT后中位生存时间22个月(95%CI 13.6-30.4个月),每次HSRT的中位缓解持续时间5个月(95%CI 3.67-6.32个月),中位野内再照射时间15个月(95%CI 9.76-20.24个月)。
关键数值与推荐
- HSRT分三个皮肤区域:头颈、躯干和手臂、腿部。
- 常用剂量方案为20 Gy分10次。
- 骨髓抑制(≥3级)在躯干和手臂HSRT中发生率为94.1%。
临床怎么用
- HSRT可用于原发性皮肤淋巴瘤的姑息治疗,但需密切监测骨髓抑制,尤其是躯干和手臂照射时。
- 对于需要覆盖全身皮肤表面的原发性皮肤淋巴瘤,TSEBT仍为标准治疗选择。
局限性
- 回顾性研究,样本量较小(24例患者,53个皮肤区域)。
- 中位随访时间较短(13个月)。
- 单中心经验,HSRT技术复杂度与不确定性需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Total skin electron beam therapy (TSEBT) is useful for primary cutaneous lymphoma. However, helical skin radiation therapy (HSRT) using tomotherapy may avoid the complexity and uncertainty of TSEBT. METHODS AND MATERIALS: All patients with primary cutaneous lymphoma who underwent HSRT at our hospital between June 2015 and July 2019 were investigated, including 7 patients registered in a clinical trial approved by an institutional review board (ID UMIN000022142). HSRT was performed in 3 partitioned skin areas: head and neck, trunk and arms, and legs. RESULTS: A total of 24 patients with 53 skin areas (including 8 patients with 24 skin areas who had undergone sequential total skin irradiation), with a median follow-up time of 13 months (range, 2-50), were investigated. Twenty patients (83.3%) had mycosis fungoides (MF). For 41 of 53 (77.4%) cases, a dose of 20 Gy in 10 fractions was used. The overall response rate in the treated fields of each HSRT in patients with MF was 100%, including 38 (80.9%) complete response, 4 (8.5%) good partial response, and 5 (10.6%) partial response. Eight patients with MF who underwent sequential total skin irradiation showed a 100% complete response. For patients with MF, the median survival time after a first round of HSRT was 22 months (95% confidence interval [CI], 13.6-30.4 months), the median response duration of each HSRT was 5 months (95% CI, 3.67-6.32 months), and the median time to in-field reirradiation for each HSRT was 15 months (95% CI, 9.76-20.24 months). Bone marrow suppression (grade ≥3) often occurred (94.1%) with HSRT on trunk and arm skin. An early patient died of HSRT-caused grade 5 leukopenia. CONCLUSIONS: HSRT targeting trunk and arm skin induced severe bone marrow suppression that led to a temporary palliative effect. TSEBT should still be considered standard treatment for primary cutaneous lymphoma covering the total body surface area.
引用
- Kitaguchi M, Yamashita H, Takenaka R, et al. Helical Skin Radiation Therapy Including Total Skin Radiation Therapy Using Tomotherapy for Primary Cutaneous Lymphoma With Bone Marrow Suppression as a Related Adverse Event. Pract Radiat Oncol. 2021. PMID: 33440254. doi:10.1016/j.prro.2020.11.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。